Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRD for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC
NCT07350824Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label trial of sintilimab in hepatocellular carcinoma (HCC) (2 cohorts), sponsored by Tongji Hospital. Primary endpoint: Disease-free survival at 60 months. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07350824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07350824.